US Lifts Suspension on Johnson & Johnson Covid-19 Jab, Says Administration Will Resume Immediately
The vaccine had been temporarily shelved after allegations that some people had developed blood clotting issues after getting the jab.
The United States (US) government has announced an immediate resumption of the Johnson & Johnson Covid-19 vaccine issuance.
This following after the lifting of the temporary ban previously slapped on the jab. The resumption ends a 10-day ban over the jab in what had been described as rare but fatal blood clots.
Centers for Disease Control and Prevention (CDC) as well as Food and Drug Administration (FDA) noted that the clotting issue cases were reportedly low.
According to the investigations by CDC and FDA, only 15 clotting cases out of 8 million people vaccinated were reported. "We are no longer recommending a pause in the use of this vaccine," stated CDC Director Rochelle Walensky.
The Director added that although the clotting cases were likely, the chances were very minimal. The announcement meant that the resumption was set to kick off with an immediate effect starting Saturday (today)
Unlike Pfizer and Moderna vaccines which must be administered two doses per recipient to achieve efficiency, Johnson & Johnson vaccine can be issued as a single dose and still serve the purpose.
J&J vaccine storage requirements are also not so demanding, meaning that the jab may serve the purpose to the hard-to-reach regions.
However, the vaccine will in the meantime remain limited to those aged 18 years and above. The US has reportedly fully vaccinated 35% of its adult population, while another 53% have got at least a single Covid-19 jab.